Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Hematopoietic Syndrome Due to Acute Radiation Syndrome Clinical Trial

Official title: A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects

Status Completed

Clinical Trial Summary

This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.

Clinical Trial Description

A randomized, placebo-controlled, double-blind study of HemaMax to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single 12 μg subcutaneous dose of HemaMax on 60 healthy subjects for 28 days after HemaMax administration. ;

Related Conditions & MeSH terms

• Acute Radiation Syndrome
• Hematopoietic Syndrome Due to Acute Radiation Syndrome
• Radiation Injuries

• NCT number: NCT01742221
• Study type: Interventional
• Source: Neumedicines Inc.
• Status: Completed
• Phase: Phase 1
• Start date: August 2012
• Completion date: December 2012